Detalhe da pesquisa
1.
Multiple sclerosis mortality in New Zealand: a nationwide prospective study.
J Neurol Neurosurg Psychiatry
; 94(7): 511-517, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36882223
2.
The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis.
Mult Scler
; 28(5): 831-841, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34387513
3.
The latitude gradient for multiple sclerosis prevalence is established in the early life course.
Brain
; 144(7): 2038-2046, 2021 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33704407
4.
Incidence and prevalence of NMOSD in Australia and New Zealand.
J Neurol Neurosurg Psychiatry
; 88(8): 632-638, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28550069
5.
A new era in the treatment of multiple sclerosis.
Med J Aust
; 203(3): 139-41, 141e.1, 2015 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26224184
6.
Reduced grey matter perfusion without volume loss in early relapsing-remitting multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 85(5): 544-51, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24039024
7.
Multiple sclerosis in New Zealand Maori.
Mult Scler
; 20(14): 1892-5, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24852927
8.
Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand.
Eur J Health Econ
; 24(6): 939-950, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36149605
9.
NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand.
J Neurol
; 269(2): 836-845, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34213614
10.
Response to treatment in NMOSD: the Australasian experience.
Mult Scler Relat Disord
; 58: 103408, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35216788
11.
An investigation of the relationship between latitude and multiple sclerosis severity in New Zealand.
Mult Scler
; 22(5): 705-7, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26432856
12.
MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis.
Front Neurol
; 12: 722237, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34566866
13.
MS prevalence in New Zealand, an ethnically and latitudinally diverse country.
Mult Scler
; 16(12): 1422-31, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20813774
14.
The neuro-otology of Susac syndrome.
J Neurol
; 267(12): 3711-3722, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32696340
15.
Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation.
Front Neurol
; 11: 537, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32612571
16.
The clinical profile of NMOSD in Australia and New Zealand.
J Neurol
; 267(5): 1431-1443, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32006158
17.
Acute inflammatory encephalomyelitis following Campylobacter enteritis associated with high titre antiganglioside GM1 IgG antibodies.
J Clin Neurosci
; 16(4): 597-8, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19200732
18.
Functional Connectivity Alterations Reveal Complex Mechanisms Based on Clinical and Radiological Status in Mild Relapsing Remitting Multiple Sclerosis.
Front Neurol
; 9: 690, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30177910
19.
Helsinki Stroke Model Is Transferrable With "Real-World" Resources and Reduced Stroke Thrombolysis Delay to 34 min in Christchurch.
Front Neurol
; 9: 290, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29760676
20.
Disability profile of multiple sclerosis in New Zealand.
J Clin Neurosci
; 28: 97-101, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-26765754